| OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer (NCT05232136) | Binhui Biopharmaceutical Co., Ltd. | 2022-07-11 |
| A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (NCT05327647) | CHU de Quebec-Universite Laval | 2022-06-23 |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05375903) | UroGen Pharma Ltd. | 2022-06-01 |
| Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer (NCT05337397) | Jørgen Bjerggaard Jensen | 2022-05-01 |
| Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients (NCT05332353) | Mansoura University | 2022-04-01 |
| Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) (NCT05085977) | Protara Therapeutics | 2022-03-10 |
| Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer (NCT06205277) | University of Trieste | 2022-01-01 |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05014139) | Astellas Pharma Global Development, Inc. | 2021-12-07 |
| Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment (NCT05126472) | Memorial Sloan Kettering Cancer Center | 2021-11-08 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients (NCT04736394) | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 2021-09-29 |
| LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors (NCT04690699) | Istari Oncology, Inc. | 2021-08-01 |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve (NCT04752722) | enGene, Inc. | 2021-04-22 |
| Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer (NCT04859751) | Qilu Pharmaceutical Co., Ltd. | 2021-03-23 |
| Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention (NCT04375813) | Robert Svatek | 2021-01-25 |
| Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study (NCT05626101) | Al-Azhar University | 2021-01-01 |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (NCT04387461) | CG Oncology, Inc. | 2020-12-08 |
| Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder Cancer (NCT04664816) | Mansoura University | 2020-12-01 |
| Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer (NCT04644835) | Mansoura University | 2020-11-28 |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (NCT04452591) | CG Oncology, Inc. | 2020-10-27 |
| A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors (NCT03914794) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-10-02 |
| Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer (NCT03950362) | Institut Paoli-Calmettes | 2020-06-15 |
| Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer (NCT05675176) | National and Kapodistrian University of Athens | 2020-04-12 |
| Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer (NCT05671900) | Clinical Hospital Centre Zagreb | 2020-04-01 |
| Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer (NCT06235853) | Wroclaw Medical University | 2020-01-01 |
| A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (NCT04165317) | Pfizer | 2019-12-30 |
| Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor (NCT04100733) | Jørgen Bjerggaard Jensen | 2019-11-01 |
| Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer (NCT06020807) | Nucleix Ltd. | 2019-09-05 |
| Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy (NCT04943094) | Aarhus University Hospital | 2019-09-01 |
| CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (NCT03933826) | University of Washington | 2019-07-09 |
| Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC) (NCT06767982) | Ankara University | 2019-01-01 |
| A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X) (NCT03664258) | Cepheid | 2018-06-06 |
| A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer (NCT03560479) | Hamlet Pharma AB | 2018-05-21 |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (NCT03081858) | Lipac Oncology LLC | 2018-05-17 |
| Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (NCT03528694) | AstraZeneca | 2018-05-14 |
| Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) (NCT03421236) | Patrice Jichlinski | 2018-02-18 |
| "En Bloc" Resection of NMIBC: a Prospective， Single Centre，Randomized Study (NCT03221062) | Tongji Hospital | 2017-08-01 |
| Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients (NCT04490993) | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 2017-03-30 |
| Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC (NCT02982395) | Samyang Biopharmaceuticals Corporation | 2017-01-01 |
| Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC (NCT02895620) | Institut Claudius Regaud | 2016-08-01 |
| Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer (NCT02969109) | Genomic Health®, Inc. | 2015-10-01 |
| CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) (NCT02316171) | Viralytics | 2015-01-16 |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (NCT02138734) | ImmunityBio, Inc. | 2014-07-21 |
| Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy (NCT04498702) | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 2014-05-13 |
| Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer (NCT02075060) | Poitiers University Hospital | 2014-02-01 |
| Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. (NCT06167356) | IRCCS San Raffaele | 2013-11-27 |
| A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) (NCT01799499) | UroGen Pharma Ltd. | 2013-03-01 |
| Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer (NCT01731652) | Telormedix SA | 2013-02-01 |
| A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer (NCT01625260) | Altor BioScience | 2012-03-30 |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder (NCT01310803) | Endo USA Inc., a Keenova Therapeutics Company | 2011-05-01 |
| Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer (NCT01458847) | BioCis Pharma Ltd | 2009-10-01 |
| Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging (NCT01004211) | Paolo Puppo | 2009-08-01 |
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer (NCT02343614) | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | 2003-03-01 |
| An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG (NCT06443944) | CG Oncology, Inc. | |